The San Antonio Breast Cancer Symposium at the Henry B. Gonzalez Convention Center (Photo by MedMeetingImages/Todd Buchanan 2024)
December 13, 2024 10:57 AM EST
R&D
Pharma

CDK4 in­hibitors from BeiGene and Pfiz­er, ALX’s CD47 drug take the stage at SABCS

Ayisha Sharma

News Reporter

This year’s San An­to­nio Breast Can­cer Con­fer­ence yield­ed ma­jor clin­i­cal up­dates on some of the hottest ar­eas of on­col­o­gy, from VEGF bis­pecifics …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

A service from the Financial Times